Literature DB >> 21960168

Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial.

Jeroen K J Deegens, Jack F M Wetzels.   

Abstract

Patients with steroid-resistant focal segmental glomerulosclerosis (FSGS) may benefit from treatment with calcineurin inhibitors. A National Institutes of Health-funded FSGS multicenter study has suggested that a combination of mycophenolate mofetil and oral dexamethasone pulses was equivalent to cyclosporine. However, since the study was underpowered, one cannot draw firm conclusions from this study. The FSGS trial underscores that FSGS is not one disease and that better predictors of outcome and response to therapy are needed.

Entities:  

Mesh：

Year:  2011        PMID： 21960168     DOI： 10.1038/ki.2011.191

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  8 in total

1.  Glomerular disease: The search goes on: suPAR is not the elusive FSGS factor.

Authors:  Jeroen K Deegens; Jack F Wetzels
Journal:  Nat Rev Nephrol       Date:  2014-06-24       Impact factor: 28.314

2.  Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS.

Authors:  Ronald J Hogg; Aaron Friedman; Tom Greene; Milena Radeva; Milos N Budisavljevic; Jennifer Gassman; Debbie S Gipson; J Ashley Jefferson; Eunice G John; Frederick J Kaskel; Asha Moudgil; Marva Moxey-Mims; Luis A Ortiz; Jeffrey R Schelling; William Schnaper; Tarak Srivastava; Howard Trachtman; V Matti Vehaskari; Craig Wong; Robert P Woronieki; Scott K Van Why; Anna Zolotnitskaya
Journal:  Clin J Am Soc Nephrol       Date:  2012-11-08       Impact factor: 8.237

Review 3.  Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

Authors:  Elisabeth M Hodson; Sophia C Wong; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2016-10-11

4.  Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury.

Authors:  Ehtesham Arif; Ashish K Solanki; Pankaj Srivastava; Bushra Rahman; Wayne R Fitzgibbon; Peifeng Deng; Milos N Budisavljevic; Catalin F Baicu; Michael R Zile; Judit Megyesi; Michael G Janech; Sang-Ho Kwon; Justin Collier; Rick G Schnellmann; Deepak Nihalani
Journal:  Kidney Int       Date:  2019-05-06       Impact factor: 10.612

5.  Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up.

Authors:  Ann Christin Gjerstad; Rannveig Skrunes; Camilla Tøndel; Anders Åsberg; Sabine Leh; Claus Klingenberg; Henrik Døllner; Clara Hammarstrøm; Anna Kristina Bjerre
Journal:  Pediatr Nephrol       Date:  2022-08-22       Impact factor: 3.651

6.  Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT).

Authors:  Maria Ferris; Victoria Norwood; Milena Radeva; Jennifer J Gassman; Amira Al-Uzri; David Askenazi; Tej Matoo; Maury Pinsk; Amita Sharma; William Smoyer; Jenna Stults; Shefali Vyas; Robert Weiss; Debbie Gipson; Frederick Kaskel; Aaron Friedman; Marva Moxey-Mims; Howard Trachtman
Journal:  Clin Transl Sci       Date:  2012-10-30       Impact factor: 4.689

7.  Pediatric nephrologists' beliefs regarding randomized controlled trials.

Authors:  Aaron G Wightman; Assaf P Oron; Jordan M Symons; Joseph T Flynn
Journal:  J Investig Med       Date:  2014-01       Impact factor: 2.895

Review 8.  Focal segmental glomerulosclerosis: molecular genetics and targeted therapies.

Authors:  Ying Maggie Chen; Helen Liapis
Journal:  BMC Nephrol       Date:  2015-07-09       Impact factor: 2.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.